Abstract
Sickle cell disease (SCD) is an inherited blood disorder characterized by vaso-occlusive crises (VOCs). Crizanlizumab infusion was FDA approved in 2019 to reduce VOCs in patients with SCD ≥16 years old. There is little real-world evidence (RWE) regarding crizanlizumab use.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
